The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Wedbush on September 12, 2023. The analyst firm set a price target for $38.00 expecting DAWN to rise to within 12 months (a possible 204.24% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Wedbush, and Day One Biopharmaceutical reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $38.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.49, which is within the analyst’s predicted range.

The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Wedbush on September 12, 2023. The analyst firm set a price target for $38.00 expecting DAWN to rise to within 12 months (a possible 204.24% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Wedbush, and Day One Biopharmaceutical reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $38.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.49, which is within the analyst’s predicted range.

The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Wedbush on September 12, 2023. The analyst firm set a price target for $38.00 expecting DAWN to rise to within 12 months (a possible 204.24% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Wedbush, and Day One Biopharmaceutical reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $38.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.49, which is within the analyst’s predicted range.

The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Wedbush on September 12, 2023. The analyst firm set a price target for $38.00 expecting DAWN to rise to within 12 months (a possible 204.24% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Wedbush, and Day One Biopharmaceutical reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $38.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.49, which is within the analyst’s predicted range.

The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Wedbush on September 12, 2023. The analyst firm set a price target for $38.00 expecting DAWN to rise to within 12 months (a possible 204.24% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Wedbush, and Day One Biopharmaceutical reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $38.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.49, which is within the analyst’s predicted range.

The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Wedbush on September 12, 2023. The analyst firm set a price target for $38.00 expecting DAWN to rise to within 12 months (a possible 204.24% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Wedbush, and Day One Biopharmaceutical reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $38.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.49, which is within the analyst’s predicted range.

The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Wedbush on September 12, 2023. The analyst firm set a price target for $38.00 expecting DAWN to rise to within 12 months (a possible 204.24% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Wedbush, and Day One Biopharmaceutical reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $38.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.49, which is within the analyst’s predicted range.

The latest price target for Day One Biopharmaceutical (NASDAQ: DAWN) was reported by Wedbush on September 12, 2023. The analyst firm set a price target for $38.00 expecting DAWN to rise to within 12 months (a possible 204.24% upside). 24 analyst firms have reported ratings in the last year.

The latest analyst rating for Day One Biopharmaceutical (NASDAQ: DAWN) was provided by Wedbush, and Day One Biopharmaceutical reiterated their outperform rating.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Day One Biopharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Day One Biopharmaceutical was filed on September 12, 2023 so you should expect the next rating to be made available sometime around September 12, 2024.

While ratings are subjective and will change, the latest Day One Biopharmaceutical (DAWN) rating was a reiterated with a price target of $0.00 to $38.00. The current price Day One Biopharmaceutical (DAWN) is trading at is $12.49, which is within the analyst’s predicted range.